Review finds greater heart risk in anti-smoking drug Chantix

07/5/2011 | Reuters

A meta-analysis in the Canadian Medical Association Journal found that healthy, middle-age users of Chantix, Pfizer's smoking-cessation drug, had a 72% greater risk of heart problems requiring hospitalization compared with placebo users. Last month, the FDA said Chantix's warning label will be revised to mention increased cardiovascular risk in those with a history of heart disease. Pfizer is working with the agency "to conduct a combined analysis of clinical-trial data" that "will help further evaluate the cardiovascular safety of Chantix," the company said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC